Medexus Pharmaceuticals (TSE:MDP) Stock Rating Lowered by Stifel Nicolaus

Medexus Pharmaceuticals (TSE:MDP) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Friday,BayStreet.CA reports. They presently have a C$3.45 price objective on the stock, down from their previous price objective of C$6.00. Stifel Nicolaus’ price objective points to a potential upside of 3.92% from the company’s current price.

Several other research analysts have also commented on the stock. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Ventum Financial raised their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and five have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Strong Buy” and a consensus price target of C$5.49.

Medexus Pharmaceuticals Price Performance

MDP traded up C$0.27 during midday trading on Friday, reaching C$3.32. 153,563 shares of the company’s stock traded hands, compared to its average volume of 197,342. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The firm has a fifty day moving average of C$3.53 and a two-hundred day moving average of C$2.82. The stock has a market capitalization of C$81.44 million, a price-to-earnings ratio of 66.40 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.